Table 5.
Characteristics of included studies (n = 33)
| No | First author, year | Title | Setting | 2013 GDP per capita (I$) | Model | Interventions compareda | Perspective | Quality assessment score |
|---|---|---|---|---|---|---|---|---|
| 1 | Aponte-Gonzalez et al. 2013 [20] | Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia | Colombia | 12,424 | Static progression model | No prevention, vaccination (bivalent and quadrivalent) | Societal perspective | 22/22 |
| 2 | Berkhof et al. 2013 [21] | Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia | Uzbekistan, Kyrgyzstan, Georgia, Armenia, Ukraine, Bosnia and Herzegovina, Turkmenistan, Albania, Macedonia, Montenegro, Serbia, Romania, Bulgaria | 3213–14,004 | Static proportionate outcomes model | No prevention, vaccination | Health care payer’s perspective (most likely) | 22/22 |
| 3 | Campos et al. 2012 [22] | Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa | Kenya, Mozambique, Tanzania, Uganda | Kenya 2795; Mozambique 1105; Tanzania 2443; Uganda 1674 | Static progression model | No prevention, vaccination, screening | Societal perspective | 19/22 |
| 4 | Canfell et al. 2011 [23] | Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies | Rural China | 11,907 | Hybrid model (dynamic model interfaced with a cohort model) | No prevention, vaccination, screening | Societal perspective | 20/21 |
| 5 | Colantonio et al. 2009 [24] | Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries | Argentina, Brazil, Chile, Mexico, Perub | 11,774–15,038 | Static progression model | Vaccination, screening | Health provider’s perspective | 22/22 |
| 6 | Diaz et al. 2008 [25] | Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India | India | 5418 | Static Progression model | No prevention, vaccination, screening | Societal | 20/22 |
| 7 | Fonseca et al. 2013 [26] | Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region | Brazil | 15,038 | Static progression model | Vaccination, screening | Provider’s perspective | 21/22 |
| 8 | Ginsberg et al. 2009 [27] | Screening, prevention and treatment of cervical cancer—a global and regional generalized cost-effectiveness analysis | Multi-country | Varies | State proportionate outcome model | No prevention, vaccination, screening | Health providers perspective | 20/22 |
| 9 | Goldie et al. 2007 [30] | Cost-effectiveness of HPV 16, 18 vaccination in Brazil | Brazil | 15,038 | Static progression model | No prevention, vaccination, screening | Societal perspective | 20/22 |
| 10 | Goldie et al. 2008 [28] | Mathematical models of cervical cancer prevention in Latin America and the Caribbean | 33 countries in Latin America and the Caribbean | Varies | Static proportionate outcome model and a microsimulation model (for 8 countries) | Vaccination, screening | Societal perspective | 21/22 |
| 11 | Goldie et al. 2008 [29] | Mathematical models of cervical cancer prevention in the Asia Pacific region | 25 Asian countries (22 Gavi eligible countries) | Varies | Static proportionate outcome model and a microsimulation model (for 2 countries) | No prevention, vaccination, screening (for selected countries) | Societal perspective | 20/22 |
| 12 | Goldie et al. 2008 [32] | Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries | 72 Gavi-eligible countries | Varies | Static proportionate outcome model and microsimulation model of selected countries (for comparative validation) | No prevention, vaccination | Societal perspective | 21/22 |
| 13 | Goldie et al. 2012 [31] | Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru | Peru | 11,774 | Static microsimulation model | No prevention, vaccination, screening | Societal perspective | 20/22 |
| 14 | Gutierrez-Aguado, 2011 [33] | Cost-utility of the vaccine against the human papiloma virus in Peruvian women | Peru | 11,774 | Static progression model | No prevention, vaccination | Health provider’s perspective | 22/22 |
| 15 | Gutierrez-Delgado et al. 2008 [34] | Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: results of a Markov model from the public sector perspective | Mexico | 16,370 | Static progression model | No prevention, vaccination, screening | Health provider’s perspective | 20/22 |
| 16 | Insinga et al. 2007 [35] | Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation | Mexico | 16,370 | Transmission dynamic model | Vaccination (boys and girls), screening | Health provider’s perspective | 22/22 |
| 17 | Jit et al. 2014 [36] | Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study | 179 Gavi-eligible countries | Varies | Static proportionate outcomes model | No prevention, vaccination | Varies | 22/22 |
| 18 | Kawai et al. 2012 [37] | Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model | Brazil | 15,038 | Transmission dynamic model | No prevention, vaccination, catch-up vaccination (12- to 26-year-old females) | Health system perspective | 21/22 |
| 19 | Khatibi et al. 2014 [38] | Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran | Iran | 15,590 | Static proportionate outcomes model | No prevention, vaccination | Health provider’s perspective | 22/22 |
| 20 | Kiatpongsan and Kim, 2014 [39] | Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries | Kenya, Uganda | Kenya 2795; Uganda 1674 | Static progression model | No prevention, vaccination | Not specified | 21/21 |
| 21 | Kim et al. 2007 [40] | The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting | Brazil | 15,038 | Transmission dynamic model | No prevention, vaccination (boys and girls), catch-up vaccination (12- to 26-year-old females) | Societal perspective | 21/22 |
| 22 | Kim et al. 2008 [42] | Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy | Vietnam | 5294 | Static progression model | No prevention, vaccination, screening | Societal perspective | 22/22 |
| 23 | Kim et al. 2011 [44] | Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden | 72 Gavi-eligible countries | Varies | Static proportionate outcomes model | No prevention, vaccination | Societal perspective | 20/22 |
| 24 | Kim et al. 2013 [41] | Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa | 48 sub-Saharan African countries | Varies | Static proportionate outcomes model and static progression model (for South Africa and Uganda) | No prevention, vaccination, screening (South Africa and Uganda) | Societal perspective | 22/22 |
| 25 | Kim et al. 2013 [43] | Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA) | 20 Extended Middle East and North African countries | Varies | Static proportionate outcomes model and static progression model (for Algeria, Lebanon, Turkey) | No prevention, vaccination, screening (Algeria, Lebanon, Turkey) | Societal perspective | 22/22 |
| 26 | Levin et al. 2015 [45] | An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China | China | 11,907 | Static microsimulation model | Vaccination, screening | Societal perspective | 21/22 |
| 27 | Praditsitthikorn et al. 2011 [46] | Economic evaluation of policy options for prevention and control of cervical cancer in Thailand | Thailand | 14,394 | Static progression model | No prevention, vaccination, screening | Societal and health provider’s perspective | 22/22 |
| 28 | Reynales-Shigematsu et al. 2009 [47] | Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico | Mexico | 16,370 | Static progression model | No prevention, vaccination, screening | Health provider’s perspective | 22/22 |
| 29 | Sharma et al. 2012 [48] | Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand | Thailand | 14,394 | Static progression model | No prevention, vaccination, screening | Societal perspective | 22/22 |
| 30 | Sinanovic et al. 2009 [49] | The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa | South Africa | 12,867 | Static progression model | Vaccination, screening | Health provider’s and societal perspective | 22/22 |
| 31 | Termrungruanglert et al. 2012 [50] | Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries | Thailand | 14,394 | Static progression model | Vaccination, screening | Health provider’s perspective | 22/22 |
| 32 | Tracy et al. 2014 [51] | Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: a modeling-based approach | Mali | 1642 | Transmission dynamic model | No prevention, vaccination | Not specified | 19/22 |
| 33 | Vanni et al. 2012 [52] | Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach | Brazil | 15,038 | Transmission dynamic model | Vaccination, screening | Health provider’s perspective | 19/22 |
HPV human papillomavirus, I$ international dollars, LMICs low- and middle-income countries
aVaccination targets girls prior to sexual exposure (typically 9–12 years old)
bArgentina and Chile are not classed as LMICs